76 related articles for article (PubMed ID: 21830545)
1. [Pituitary carcinoma].
Nishioka H; Yamada S; Fukuhara N
Nihon Rinsho; 2011 Mar; 69 Suppl 2():212-6. PubMed ID: 21830545
[No Abstract] [Full Text] [Related]
2. Temozolomide: a novel treatment for pituitary carcinoma.
Lim S; Shahinian H; Maya MM; Yong W; Heaney AP
Lancet Oncol; 2006 Jun; 7(6):518-20. PubMed ID: 16750503
[No Abstract] [Full Text] [Related]
3. Temozolomide and pituitary adenoma.
Hueng DY; Ma HI; Sytwu HK; Liu MY
J Neurosurg; 2011 Jun; 114(6):1820: author reply 1820-1. PubMed ID: 21513431
[No Abstract] [Full Text] [Related]
4. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
Kovacs K; Scheithauer BW; Lombardero M; McLendon RE; Syro LV; Uribe H; Ortiz LD; Penagos LC
Acta Neuropathol; 2008 Feb; 115(2):261-2. PubMed ID: 17926052
[No Abstract] [Full Text] [Related]
5. Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.
van der Vlist A; Snijders TJ; Stades AME; Spliet WGM; De Vos FYFL
Neth J Med; 2017 Dec; 75(10):451-454. PubMed ID: 29256415
[TBL] [Abstract][Full Text] [Related]
6. Treatment of pituitary neoplasms with temozolomide: A review.
Marucci G
Cancer; 2011 Sep; 117(17):4101-2; author reply 4102. PubMed ID: 21387270
[No Abstract] [Full Text] [Related]
7. Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.
Lasolle H; Raverot G
Presse Med; 2016 Jun; 45(6 Pt 2):e211-6. PubMed ID: 27242211
[TBL] [Abstract][Full Text] [Related]
8. A novel use of temozolomide in a patient with malignant prolactinoma.
Byrne S; Karapetis C; Vrodos N
J Clin Neurosci; 2009 Dec; 16(12):1694-6. PubMed ID: 19818629
[TBL] [Abstract][Full Text] [Related]
9. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Kovacs K; Horvath E; Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE
Hum Pathol; 2007 Jan; 38(1):185-9. PubMed ID: 17056093
[TBL] [Abstract][Full Text] [Related]
13. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
14. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.
Bode H; Seiz M; Lammert A; Brockmann MA; Back W; Hammes HP; Thomé C
Exp Clin Endocrinol Diabetes; 2010 Nov; 118(10):760-3. PubMed ID: 20496311
[TBL] [Abstract][Full Text] [Related]
15. Use of temozolomide in aggressive pituitary tumors: case report.
Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
[TBL] [Abstract][Full Text] [Related]
16. Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
Mendola M; Passeri E; Ambrosi B; Corbetta S
J Clin Endocrinol Metab; 2014 Aug; 99(8):2623-4. PubMed ID: 24823463
[No Abstract] [Full Text] [Related]
17. Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide.
Batisse M; Raverot G; Maqdasy S; Durando X; Sturm N; Montoriol PF; Kemeny JL; Chazal J; Trouillas J; Tauveron I
Cancer Invest; 2013 Mar; 31(3):190-6. PubMed ID: 23477586
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pituitary neoplasms with temozolomide: a review.
Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide and unusual indications: review of literature.
Tatar Z; Thivat E; Planchat E; Gimbergues P; Gadea E; Abrial C; Durando X
Cancer Treat Rev; 2013 Apr; 39(2):125-35. PubMed ID: 22818211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
